Literature DB >> 7107064

Geographic pathology of latent prostatic carcinoma.

R Yatani, I Chigusa, K Akazaki, G N Stemmermann, R A Welsh, P Correa.   

Abstract

Prostates obtained at autopsy from black and white males in the United States of America, from Colombians, from Japanese migrants in Hawaii, and from Japanese in Japan (all over 50 years old) were serially step-sectioned and examined microscopically using identical techniques and diagnostic criteria. The age-adjusted overall prevalence of latent carcinoma was significantly higher in US blacks (36.9%), in US whites (34.6%) and in Colombians (31.5%) than in Japanese in Japan (20.5%). There was no significant difference in prevalence between Japanese migrants in Hawaii (25.6%) and Japanese in Japan. When the carcinomas were subdivided into latent infiltrative type (LIT) and latent non-infiltrative type (LNT), the LIT component reflected upon the overall prevalence of latent carcinoma. There was an increase in the overall prevalence of latent carcinoma and in the prevalence of LIT tumors with age in Japanese migrants to Hawaii and in Japanese of Japan but only a suggestive increase in blacks and whites in the United States. There was no significant relation between age and prevalence in Colombia. In LNT tumors, there was no consistent trend related to race or age. The size of LIT tumors was significantly greater than that of LNT tumors in all races or in each decade of total material. There were many large LIT tumors in blacks and whites in the United States. These results suggest that the prevalence of LIT tumors shows a race variation similar to the incidence of clinical carcinoma of the prostate, and that LNT tumors probably remain latent during the individual's life span.

Entities:  

Mesh:

Year:  1982        PMID: 7107064     DOI: 10.1002/ijc.2910290602

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Effects of chronic dietary exposure to genistein, a phytoestrogen, during various stages of development on reproductive hormones and spermatogenesis in rats.

Authors:  D Roberts; D N Veeramachaneni; W D Schlaff; C A Awoniyi
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

Review 2.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

Review 3.  Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy.

Authors:  Koji Mitsuzuka; Yoichi Arai
Journal:  Int J Clin Oncol       Date:  2014-08-26       Impact factor: 3.402

4.  Risk factors for prostate cancer.

Authors:  Peter H Gann
Journal:  Rev Urol       Date:  2002

5.  Incidental prostatic carcinoma: morphometry correlated with histological grade.

Authors:  R Yatani; T Shiraishi; K Akazaki; T Hayashi; L K Heilbrun; G N Stemmermann
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

Review 6.  Nutrition and prostate cancer.

Authors:  L N Kolonel
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

7.  Migration and prostate cancer: an international perspective.

Authors:  F F Angwafo
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

8.  Prostate cancer screening: Canadian guidelines 2011.

Authors:  Jonathan I Izawa; Laurence Klotz; D Robert Siemens; Wassim Kassouf; Alan So; John Jordan; Michael Chetner; Alla E Iansavichene
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

Review 9.  The safety of vasectomy: recent concerns.

Authors:  T M Farley; O Meirik; S Mehta; G M Waites
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

10.  Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers.

Authors:  M Tanaka; K Fujimoto; Y Chihara; K Torimoto; T Yoneda; N Tanaka; A Hirayama; N Miyanaga; H Akaza; Y Hirao
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-07-14       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.